查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2009200

疼痛管理藥物市場規模、佔有率、趨勢和預測：按藥物類別、適應症、分銷管道和地區分類，2026-2034 年。

Pain Management Drugs Market Size, Share, Trends and Forecast by Drug Class, Indication, Distribution Channel, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 147 Pages | 商品交期: 2-3個工作天內

價格

2025年全球疼痛管理藥物市場規模為730.4億美元。展望未來，IMARC Group預測，該市場將在2026年至2034年間以2.23%的複合年成長率成長，到2034年達到907億美元。目前，北美市場主導地位，預計2025年將佔45%的市場。該地區受益於先進的醫療基礎設施、完善的保險體系（使患者能夠廣泛獲得各種創新型疼痛治療方案）、不斷成長的老年人口中慢性疼痛疾病的高發率，以及對藥物研發的大量投入，所有這些因素共同鞏固了疼痛管理藥物的市場佔有率。

全球疼痛管理市場成長的主要驅動力是慢性疼痛疾病（包括關節炎、下背痛和神經病變疼痛）盛行率的不斷上升，這些疾病影響全球相當一部分人口。全球人口老化加劇了對有效止痛方案的需求，因為老年人更容易患上退化性肌肉骨骼疾病和術後疼痛。此外，肥胖和糖尿病神經病變等文明病負擔的加重也推動了對先進鎮痛療法的需求。經皮貼片和緩釋製劑等藥物傳遞技術的不斷進步，提高了患者的依從性和治療效果，從而促進了全球疼痛管理市場的成長。

由於多種因素，美國正崛起為疼痛管理藥物市場的重要區域。完善的醫療保健基礎設施可支持疼痛相關疾病的早期診斷和治療，而廣泛的保險覆蓋範圍則使患者能夠獲得各種疼痛管理療法。 2025年，美國食品藥物管理局（FDA）核准了Vertex Pharmaceuticals公司研發的First-in-Class非鴉片類止痛藥Journavx（舒吉三嗪）。該藥物為中度至重度急性疼痛患者提供了替代傳統鴉片類藥物的新選擇。此外，美國境內主要企業和研究機構的存在，促進了疼痛管理藥物製劑研發的持續創新，確保了旨在提高患者療效並最大限度減少副作用的新療法的充足供應。

疼痛管理藥物市場趨勢：

在向非鴉片類藥物療法過渡方面正在取得進展。

由於人們對長期使用鴉片類藥物風險的認知不斷提高，製藥業正經歷著向非鴉片類鎮痛療法的顯著轉變。醫療專業人員和政策制定者正優先開發和推廣更安全的鎮痛替代療法，包括非類固醇消炎劑、抗驚厥藥以及針對特定疼痛途徑的新型生物製藥。美國《非鴉片類藥物成癮預防法案》（NOPAIN）實施一年後進行的一項調查顯示，超過80%的醫院和手術中心減少了圍手術手術全期鴉片類藥物的處方量，並在疼痛管理方案中增加了合格的非鴉片類治療方法的使用。這一轉變得到了更新的臨床指南的支持，這些指南建議將非鴉片類藥物治療作為許多疼痛疾病（尤其是慢性肌肉骨骼疼痛和神經病變疼痛）的一線治療通訊協定。

標靶藥物傳遞技術的進展

標靶藥物傳遞系統的創新正在改變疼痛管理市場，它能夠提供更精準、更持久的鎮痛效果，同時最大限度地減少全身副作用。經皮貼片、脂質體製劑和植入式藥物遞送裝置作為長期鎮痛的首選方法，正日益受到關注。 2025年2月，Aveva藥物遞送系統公司在美國推出了非專利Fentanyl經皮貼片。本產品採用先進的基質技術，旨在提供持續穩定的鎮痛效果，同時也具備防止誤用的功能。這些技術能夠將活性成分精準、直接釋放到疼痛部位，進而減少給藥頻率，提高患者的治療順從性。

數位健康解決方案的整合

數位健康技術與疼痛管理藥物療法的融合正在改變治療模式，並影響全球疼痛管理藥物市場的趨勢。行動醫療應用程式和穿戴式裝置正與藥物介入相結合，提供全面的疼痛監測和管理解決方案。這些數位工具使醫療專業人員能夠即時追蹤患者的疼痛程度、用藥模式和治療結果，從而根據數據調整治療方案。 2025年9月，Pier 88 Health和Theranica在中國獲得了Nerivio® REN的監管核准，這是一款用於治療偏頭痛的穿戴式設備，可提供處方數位藥物。這充分體現了數位疼痛管理技術如何超越傳統藥物療法，並獲得全球臨床認可。遠端醫療平台正在擴大服務不足地區患者獲得疼痛專科醫生服務的管道，並提高複雜疼痛症狀患者的診斷和處方箋準確性。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球疼痛管理藥物市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場區隔：依藥物類別分類
  • 市場區隔：依指標
  • 市場區隔：依分銷通路分類
  • 市場區隔：按地區
  • 市場預測

第6章 市場區隔：依藥物類別分類

  • NSAIDs
  • 麻醉劑
  • 抗驚厥藥物
  • 偏頭痛藥物
  • 抗憂鬱症
  • 鴉片類藥物
  • 其他

第7章 市場區隔：依適應症分類

  • 肌肉骨骼疼痛
  • 手術和創傷性疼痛
  • 癌症疼痛
  • 神經性疼痛
  • 偏頭痛
  • 產科疼痛
  • 纖維肌痛引起的疼痛
  • 燒傷疼痛
  • 牙齒/臉部疼痛
  • 兒童痛苦
  • 其他

第8章 市場區隔：依分銷通路分類

  • 醫院藥房
  • 零售藥房
  • 網路藥房

第9章 市場區隔：依地區分類

  • 北美洲
  • 歐洲
  • 亞太地區
  • 中東和非洲
  • 拉丁美洲

第10章 SWOT 分析

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

  • 價格指標
  • 價格結構
  • 利潤分析

第14章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • Abbott Laboratories Inc.
    • AbbVie Inc.
    • Bausch+Lomb.
    • Bayer AG
    • Eli Lilly & Company
    • GSK plc
    • Pfizer Inc.
    • Purdue Pharma LP
    • Sanofi SA
    • Viatris Inc
Product Code: SR112026A1330

The global pain management drugs market size was valued at USD 73.04 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 90.70 Billion by 2034, exhibiting a CAGR of 2.23% from 2026-2034. North America currently dominates the market, holding a market share of 45% in 2025. The region benefits from its advanced healthcare infrastructure, comprehensive insurance coverage frameworks facilitating broad access to diverse and innovative pain therapies, a high prevalence of chronic pain conditions among its growing aging population, and substantial pharmaceutical research and development investments, all collectively reinforcing the pain management drugs market share.

The global pain management drugs market is being driven by the rising prevalence of chronic pain disorders, including arthritis, lower back pain, and neuropathic conditions, which affect a substantial portion of the global population. The increasing geriatric demographic worldwide is contributing to a higher demand for effective pain relief solutions, as older adults are more susceptible to degenerative musculoskeletal conditions and postoperative pain. Additionally, the growing burden of lifestyle-related ailments such as obesity and diabetes-related neuropathy is fueling the need for advanced analgesic therapies. Ongoing advancements in drug delivery technologies, including transdermal patches and extended-release formulations, are enhancing patient compliance and therapeutic outcomes, thereby supporting the pain management drugs market growth on a global scale.

The United States has emerged as a major region in the pain management drugs market owing to many factors. The well-developed healthcare infrastructure supports early diagnosis and treatment of pain-related conditions, while extensive insurance coverage facilitates patient access to a broad range of pain management therapies. In 2025, the U.S. Food and Drug Administration approved Journavx (suzetrigine) a first-in-class non-opioid analgesic developed by Vertex Pharmaceuticals offering a novel alternative to traditional opioids for moderate-to-severe acute pain. Furthermore, the presence of leading pharmaceutical companies and research institutions in the country fosters continuous innovation in pain management drug formulations, ensuring a robust pipeline of novel therapeutic agents aimed at improving efficacy and minimizing adverse effects for patients.

PAIN MANAGEMENT DRUGS MARKET TRENDS:

Growing Shift Toward Non-Opioid Therapies

The pharmaceutical industry is witnessing a significant transition toward non-opioid pain management therapies driven by heightened awareness of the risks associated with long-term opioid use. Healthcare providers and policymakers are prioritizing the development and adoption of safer analgesic alternatives, including nonsteroidal anti-inflammatory drugs, anticonvulsants, and novel biologics targeting specific pain pathways. According to reports, survey data following the first year of the U.S. Non-Opioids Prevent Addiction (NOPAIN) Act showed that over 80 % of hospitals and surgical centers reported decreasing perioperative opioid prescribing and increasing use of qualifying non-opioid options in pain protocols. This shift is reinforced by updated clinical guidelines that recommend non-opioid treatments as first-line options for many pain conditions, particularly chronic musculoskeletal and neuropathic pain.

Advancements in Targeted Drug Delivery

Innovations in targeted drug delivery systems are transforming the pain management drugs market outlook by enabling more precise and sustained analgesic effects while minimizing systemic side effects. Transdermal patches, liposomal formulations, and implantable drug delivery devices are gaining traction as preferred methods for administering pain medications over extended periods. In February 2025, Aveva Drug Delivery Systems launched its generic fentanyl transdermal patch in the U.S., using advanced matrix technology designed to provide consistent extended pain relief while incorporating features to deter misuse. These technologies allow for controlled release of active pharmaceutical ingredients directly to the site of pain, reducing the need for frequent dosing and improving patient adherence to treatment regimens.

Integration of Digital Health Solutions

The convergence of digital health technologies and pain management pharmacotherapy is reshaping treatment paradigms and influencing the pain management drugs market trends across the globe. Mobile health applications and wearable devices are being integrated with pharmaceutical interventions to provide comprehensive pain monitoring and management solutions. These digital tools enable healthcare providers to track patient pain levels, medication usage patterns, and treatment outcomes in real time, facilitating data-driven adjustments to therapeutic regimens. In September 2025, Pier 88 Health and Theranica received regulatory approval in China for the Nerivio(R) REN wearable device, a prescribed digital therapeutic for migraine that exemplifies how digital pain technologies are gaining global clinical acceptance beyond traditional drug therapy. Telemedicine platforms are expanding access to pain specialists in underserved regions, improving diagnosis and prescription accuracy for patients with complex pain conditions.

PAIN MANAGEMENT DRUGS INDUSTRY SEGMENTATION:

Analysis by Drug Class:

  • NSAIDs
  • Anesthetics
  • Anticonvulsants
  • Antimigraine Agents
  • Antidepressants
  • Opioids
  • Others

Opioids currently occupy a market share of 35%, which is a prominent category in pain management. Opioids are prescribed for moderate to severe pain conditions, such as postoperative pain, cancer pain, and advanced musculoskeletal diseases. Opioids work by interacting with opioid receptors in the central and peripheral nervous system, thus modulating pain perception. The use of opioids in the healthcare setting continues to be high due to their proven efficacy in the management of acute and chronic pain that is unresponsive to non-opioid options. Long-acting and abuse-deterrent formulations of opioids have been introduced to mitigate concerns about opioid abuse while still providing therapeutic benefits to patients who require chronic pain management. Healthcare professionals are increasingly turning to multimodal therapy that combines opioids with other treatments to provide improved pain relief while minimizing opioid use. Guidelines for opioid prescription continue to be refined to ensure prudent use while providing patients with access to pain management options.

Analysis by Indication:

  • Musculoskeletal Pain
  • Surgical and Trauma Pain
  • Cancer Pain
  • Neuropathic Pain
  • Migraine Pain
  • Obstetrical Pain
  • Fibromyalgia Pain
  • Burn Pain
  • Dental/Facial Pain
  • Pediatric Pain
  • Others

Musculoskeletal pain leads the market with a share of 38%. Musculoskeletal pain encompasses a broad spectrum of conditions affecting bones, joints, muscles, tendons, and ligaments, making it one of the most prevalent pain categories globally. The high demand for medications targeting musculoskeletal pain is driven by the increasing incidence of osteoarthritis, rheumatoid arthritis, lower back pain, and sports-related injuries across diverse demographic groups. Aging populations worldwide are particularly susceptible to degenerative joint diseases and spinal disorders, sustaining consistent demand for effective pharmacological interventions. Treatment protocols for musculoskeletal pain typically involve nonsteroidal anti-inflammatory drugs, muscle relaxants, corticosteroids, and topical analgesics, with biologic therapies gaining prominence for refractory cases. The rising adoption of combination therapies and the development of disease-modifying agents are positively influencing the pain management drugs market forecast for this indication. Rehabilitation-focused treatment strategies that integrate pharmacotherapy with physical therapy are becoming standard practice, enhancing overall patient outcomes and driving sustained demand for targeted musculoskeletal pain medications.

Analysis by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Hospital pharmacies account for the largest market share of 55%, as they are the main distribution channel for pain management medications due to their direct link with the healthcare system. These pharmacies handle the distribution of controlled medications such as opioids and anesthetics. They are regulated by the relevant authorities to ensure that patients receive the medication correctly. The main reason for the large market share of hospital pharmacies is that they play a crucial role in the management of acute pain, surgical pain, and pain resulting from chronic illnesses. The hospital pharmacists work in collaboration with pain management teams to ensure that the drug selection and monitoring programs are optimized for individual patients. The rising number of surgeries, trauma cases, and cancer treatments in hospitals continues to drive the market through this distribution channel. The hospital pharmacies also handle formulary and bulk purchases that affect prescribing practices and ensure that patients have access to a wide range of analgesic medications at an affordable cost.

Regional Analysis:

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Latin America

North America, with a market share of 45%, retaining the leading market position. The region enjoys a well-developed healthcare infrastructure with a strong focus on sophisticated diagnostic facilities, comprehensive insurance coverage, and universal access to both primary and specialty pain management care. The large number of patients with chronic pain conditions such as lower back pain, arthritis, and neuropathies in the region supports strong demand for various analgesic treatments. Well-developed pharmaceutical research infrastructure and the presence of major pharmaceutical companies in the region have helped to ensure steady innovation in pain management products, such as abuse-deterrent opioid formulations and new non-opioid modalities. Government policies to counter opioid abuse have spurred the development and launch of safer pain management products, promoting the concept of multimodal pain management. Reimbursement-friendly policies and government-sponsored pain management programs have also helped to ensure better accessibility to prescription pain management products in the region.

KEY REGIONAL TAKEAWAYS:

UNITED STATES PAIN MANAGEMENT DRUGS MARKET ANALYSIS

The United States represents a significant contributor to the pain management drugs market within North America, supported by the high prevalence of chronic and acute pain conditions across the population. The country possesses a well-established pharmaceutical ecosystem with robust research and development capabilities focused on developing next-generation analgesic therapies. In August 2025, the U.S. FDA approved Tonmya a non-opioid treatment for fibromyalgia-related pain, marking the first new therapy for this chronic pain condition in over 15 years and expanding patient options beyond traditional drugs. Healthcare providers are increasingly adopting evidence-based pain management protocols that integrate pharmacological treatments with complementary and alternative approaches, reflecting the evolving clinical landscape. The regulatory environment has shifted toward encouraging non-opioid alternatives, with expedited approval pathways for novel pain therapeutics that demonstrate improved safety profiles. The growing emphasis on personalized medicine is driving the development of genetic testing tools that help clinicians identify optimal pain medications for individual patients, reducing trial-and-error prescribing. Additionally, the expansion of outpatient pain management clinics and ambulatory surgical centers is diversifying drug distribution channels and improving access for patients in rural and underserved communities.

EUROPE PAIN MANAGEMENT DRUGS MARKET ANALYSIS

The European market for pain management drugs is driven by a complex regulatory environment and well-established national healthcare systems that ensure widespread patient access to analgesic treatments. The region has a large burden of chronic pain disorders such as osteoarthritis, rheumatoid arthritis, and cancer pain, which continues to fuel demand for effective pharmacologic therapies. The European regulatory bodies have established tough guidelines for the use of opioids, thus encouraging the use of non-opioid alternatives and multimodal approaches to pain management. The focus on value-based healthcare in the major European economies is shaping formulary inclusion and encouraging the use of cost-effective generic analgesics in combination with innovative branded therapies. Research organizations and pharmaceutical companies in the region are working together on clinical trials for new pain therapies, including biologic and gene therapies that target specific pain pathways. In addition, the aging population in Western European nations is fueling the burden of degenerative musculoskeletal disorders, thus sustaining demand for long-term pain management strategies and rehabilitation pharmacotherapy.

ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET ANALYSIS

The Asia-Pacific pain management drugs market is experiencing significant expansion driven by improving healthcare infrastructure, growing awareness of pain management options, and increasing healthcare expenditure across developing economies. The large and aging population base in countries throughout the region contributes to a rising burden of chronic pain conditions, including osteoarthritis, diabetic neuropathy, and cancer-related pain. Government initiatives aimed at expanding universal health coverage and improving access to essential medications are supporting increased utilization of analgesic therapies. The growing middle-class population with enhanced purchasing power is driving demand for advanced branded pain medications in addition to affordable generic alternatives. The region is also witnessing increased investment in pharmaceutical manufacturing capabilities, enabling local production of pain management drugs and reducing dependence on imports.

LATIN AMERICA PAIN MANAGEMENT DRUGS MARKET ANALYSIS

The Latin American pain management drugs market is expanding as healthcare infrastructure development progresses across the region, improving access to diagnostic and therapeutic services for pain management. The growing burden of chronic diseases, including diabetes and cardiovascular conditions, is increasing the prevalence of associated pain disorders that require pharmacological intervention. Government healthcare reforms aimed at expanding medication coverage and reducing out-of-pocket expenses are supporting broader patient access to analgesic therapies. The increasing urbanization across the region is facilitating greater awareness of pain treatment options and improving distribution networks for pharmaceutical products. Local generic drug manufacturers are playing a vital role in expanding access.

MIDDLE EAST AND AFRICA PAIN MANAGEMENT DRUGS MARKET ANALYSIS

The Middle East and Africa pain management drugs market is developing steadily as regional healthcare systems undergo modernization and expansion. Growing government investment in healthcare infrastructure is improving access to pain management services, particularly in urban centers across the region. The increasing prevalence of chronic pain conditions linked to lifestyle changes, aging demographics, and road traffic injuries is driving demand for analgesic medications. International pharmaceutical companies are expanding their presence in the region through strategic partnerships with local distributors. Regulatory frameworks governing controlled substance distribution are evolving, facilitating safer and broader access to essential pain management medications for underserved populations.

COMPETITIVE LANDSCAPE:

The pain management drugs market is characterized by intense competition among established pharmaceutical companies, generic drug manufacturers, and emerging biotechnology firms. Major market players are focusing on expanding their product portfolios through the development of novel analgesic formulations, including abuse-deterrent opioids, non-opioid alternatives, and targeted biologic therapies. Strategic initiatives such as mergers, acquisitions, and licensing agreements are being pursued to strengthen market positions and gain access to innovative drug delivery technologies. Companies are investing heavily in clinical research to advance pipeline candidates through regulatory approval processes, with particular emphasis on drugs addressing unmet medical needs in chronic and neuropathic pain management. Competitive differentiation is being achieved through the development of extended-release formulations, combination therapies, and patient-centric drug delivery systems.

The report provides a comprehensive analysis of the competitive landscape in the pain management drugs market with detailed profiles of all major companies, including:

  • Abbott Laboratories Inc.
  • AbbVie Inc.
  • Bausch + Lomb.
  • Bayer AG
  • Eli Lilly & Company
  • GSK plc
  • Pfizer Inc.
  • Purdue Pharma L.P.
  • Sanofi S.A
  • Viatris Inc

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the pain management drugs market?

2. What is the future outlook of the pain management drugs market?

3. What are the key factors driving the pain management drugs market?

4. Which region accounts for the largest pain management drugs market share?

5. Which are the leading companies in the global pain management drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Pain Management Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Breakup by Drug Class
  • 5.5 Market Breakup by Indication
  • 5.6 Market Breakup by Distribution Channel
  • 5.7 Market Breakup by Region
  • 5.8 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 NSAIDs
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Anesthetics
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Anticonvulsants
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Antimigraine Agents
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Antidepressants
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Opioids
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Indication

  • 7.1 Musculoskeletal Pain
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Surgical and Trauma Pain
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Cancer Pain
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Neuropathic Pain
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Migraine Pain
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Obstetrical Pain
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Fibromyalgia Pain
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast
  • 7.8 Burn Pain
    • 7.8.1 Market Trends
    • 7.8.2 Market Forecast
  • 7.9 Dental/Facial Pain
    • 7.9.1 Market Trends
    • 7.9.2 Market Forecast
  • 7.10 Pediatric Pain
    • 7.10.1 Market Trends
    • 7.10.2 Market Forecast
  • 7.11 Others
    • 7.11.1 Market Trends
    • 7.11.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Retail Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Pharmacies
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Europe
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Asia Pacific
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Middle East and Africa
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Latin America
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

  • 13.1 Price Indicators
  • 13.2 Price Structure
  • 13.3 Margin Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories Inc.
    • 14.3.2 AbbVie Inc.
    • 14.3.3 Bausch + Lomb.
    • 14.3.4 Bayer AG
    • 14.3.5 Eli Lilly & Company
    • 14.3.6 GSK plc
    • 14.3.7 Pfizer Inc.
    • 14.3.8 Purdue Pharma L.P.
    • 14.3.9 Sanofi S.A
    • 14.3.10 Viatris Inc

List of Figures

  • Figure 1: Global: Pain Management Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Pain Management Drugs Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Pain Management Drugs Market: Breakup by Drug Class (in %), 2025
  • Figure 4: Global: Pain Management Drugs Market: Breakup by Indication (in %), 2025
  • Figure 5: Global: Pain Management Drugs Market: Breakup by Distribution Channel (in %), 2025
  • Figure 6: Global: Pain Management Drugs Market: Breakup by Region (in %), 2025
  • Figure 7: Global: Pain Management Drugs Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 8: Global: Pain Management Drugs Industry: SWOT Analysis
  • Figure 9: Global: Pain Management Drugs Industry: Value Chain Analysis
  • Figure 10: Global: Pain Management Drugs Industry: Porter's Five Forces Analysis
  • Figure 11: Global: Pain Management Drugs (NSAIDs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Pain Management Drugs (NSAIDs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Pain Management Drugs (Anesthetics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Pain Management Drugs (Anesthetics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Pain Management Drugs (Anticonvulsants) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Pain Management Drugs (Anticonvulsants) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Pain Management Drugs (Antimigraine Agents) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Pain Management Drugs (Antimigraine Agents) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Pain Management Drugs (Antidepressants) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Pain Management Drugs (Antidepressants) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Pain Management Drugs (Opioids) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Pain Management Drugs (Opioids) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Pain Management Drugs (Other Drug Classes) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Pain Management Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Pain Management Drugs (Musculoskeletal Pain) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Pain Management Drugs (Musculoskeletal Pain) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Pain Management Drugs (Surgical and Trauma Pain) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Pain Management Drugs (Surgical and Trauma Pain) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Global: Pain Management Drugs (Cancer Pain) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Global: Pain Management Drugs (Cancer Pain) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: Global: Pain Management Drugs (Neuropathic Pain) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Global: Pain Management Drugs (Neuropathic Pain) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Global: Pain Management Drugs (Migraine Pain) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Global: Pain Management Drugs (Migraine Pain) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Global: Pain Management Drugs (Obstetrical Pain) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Global: Pain Management Drugs (Obstetrical Pain) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: Global: Pain Management Drugs (Fibromyalgia Pain) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: Global: Pain Management Drugs (Fibromyalgia Pain) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: Global: Pain Management Drugs (Burn Pain) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: Global: Pain Management Drugs (Burn Pain) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: Global: Pain Management Drugs (Dental/Facial Pain) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: Global: Pain Management Drugs (Dental/Facial Pain) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: Global: Pain Management Drugs (Pediatric Pain) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: Global: Pain Management Drugs (Pediatric Pain) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: Global: Pain Management Drugs (Other Indications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: Global: Pain Management Drugs (Other Indications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Global: Pain Management Drugs Market: Sales through Hospital Pharmacies (in Million USD), 2020 & 2025
  • Figure 48: Global: Pain Management Drugs Market Forecast: Sales through Hospital Pharmacies (in Million USD), 2026-2034
  • Figure 49: Global: Pain Management Drugs Market: Sales through Retail Pharmacies (in Million USD), 2020 & 2025
  • Figure 50: Global: Pain Management Drugs Market Forecast: Sales through Retail Pharmacies (in Million USD), 2026-2034
  • Figure 51: Global: Pain Management Drugs Market: Sales through Online Pharmacies (in Million USD), 2020 & 2025
  • Figure 52: Global: Pain Management Drugs Market Forecast: Sales through Online Pharmacies (in Million USD), 2026-2034
  • Figure 53: North America: Pain Management Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: North America: Pain Management Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: Europe: Pain Management Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: Europe: Pain Management Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: Asia Pacific: Pain Management Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: Asia Pacific: Pain Management Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Middle East and Africa: Pain Management Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Middle East and Africa: Pain Management Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Latin America: Pain Management Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Latin America: Pain Management Drugs Market Forecast: Sales Value (in Million USD), 2026-2034

List of Tables

  • Table 1: Global: Pain Management Drugs Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Pain Management Drugs Market Forecast: Breakup by Drug Class (in Million USD), 2026-2034
  • Table 3: Global: Pain Management Drugs Market Forecast: Breakup by Indication (in Million USD), 2026-2034
  • Table 4: Global: Pain Management Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2026-2034
  • Table 5: Global: Pain Management Drugs Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Pain Management Drugs Market Structure
  • Table 7: Global: Pain Management Drugs Market: Key Players